Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3b, Open-label, Single-arm Study of the Efficacy and Safety of Apremilast, in Subjects With Plaque Psoriasis That is Not Adequately Controlled by Topical Therapy

NCT03930186 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT03930186
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03930186 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3b, Open-label, Single-arm Study of the Efficacy and Safety of Apremilast, in Subjects With Plaque Psoriasis That is Not Adequately Controlled by Topical Therapy
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Completed
Start date
June 17, 2019
Completion date
September 25, 2020
Enrollment
152 (actual)
Sites
56

Conditions

As the registry lists them; a condition with its own page is linked.

plaque psoriasis